UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. C型肝炎ウイルス感染治療のための直接作用型抗ウイルス薬direct acting antivirals for the treatment of hepatitis c virus infection [show details]
…HCV protease inhibitors. Sofosbuvir is a substrate of the P-glycoprotein (P-gp) drug transporter, so drugs that are potent intestinal P-gp inducers may decrease sofosbuvir levels. Thus, coadministration of …
2. リファマイシン（リファンピン、リファブチン、リファペンチン）rifamycins rifampin rifabutin rifapentine [show details]
… antituberculous drugs are discussed separately. Rifampin is a potent inducer of several drug-metabolizing enzymes as well as P-glycoprotein (P-gp) multidrug efflux transporters, which can lead to undetectable …
3. ジゴキシンによる治療：初回投与、モニタリング、および用量変更treatment with digoxin initial dosing monitoring and dose modification [show details]
…inhibit P-glycoprotein is provided separately Inducers of P-glycoprotein (eg, phenytoin, rifampin, etc), on the other hand, can decrease serum digoxin levels. A list of medicines that induce P-glycoprotein …
4. エキノカンジンの薬理学pharmacology of echinocandins [show details]
…have not been performed. Echinocandins are not significant inhibitors or inducers of cytochrome P450 metabolism or p-glycoprotein drug efflux transporters. As a result, echinocandins generally have a lower …
5. 第二世代抗精神病薬：薬理学、用法および副作用second generation antipsychotic medications pharmacology administration and side effects [show details]
…paliperidone when a strong inducer of both CYP 3A4 and P-glycoprotein 1 (eg, carbamazepine, rifampin, St. John wort) is co-administered. Conversely, on discontinuation of the strong inducer, it may be necessary …

English Journal

Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.

Elmeliegy M, Láng I, Smolyarchuk EA, Chung CH, Plotka A, Shi H, Wang D.
British journal of clinical pharmacology. 2020 Apr;86(4)771-778.
In vitro data show that talazoparib is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein transporters. This open-label, 2-arm, drug-drug interaction Phase 1 study in patients with advanced solid tumours assessed the effect of a P-gp inhibitor (itraconazole) and a P-gp induce
PMID 31770456

Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Elmeliegy M, Vourvahis M, Guo C, Wang DD.
Clinical pharmacokinetics. 2020 Feb;().
Understanding transporter-mediated drug-drug interactions (DDIs) for investigational agents is important during drug development to assess DDI liability, its clinical relevance, and to determine appropriate DDI management strategies. P-glycoprotein (P-gp) is an efflux transporter that influences the
PMID 32052379

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.

Vu L, Cox GF, Ibrahim J, Peterschmitt MJ, Ross L, Thibault N, Turpault S.
Molecular genetics and metabolism reports. 2020 Mar;22()100552.
Eliglustat is an oral glucosylceramide synthase inhibitor indicated for the long-term treatment of adults with Gaucher disease type 1 and CYP2D6 extensive, intermediate, or poor metabolizer phenotypes. Eliglustat is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4 and is a substrate
PMID 31993325

Japanese Journal

フェキソフェナジンの立体選択的体内動態とその規定因子の解析

赤嶺由美子
薬学雑誌. 乙号 135(3), 473-481, 2015
… Because fexofenadine is poorly metabolized by cytochrome P450s, its pharmacokinetics depends on its drug-transporter activities. … The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure. …
NAID 130004756523

Involvement of AP-1 and NF-κB in the Up-regulation of P-gp in Vinblastine Resistant Caco-2 Cells

CHEN Qiuxia,BIAN Yicong,ZENG Su
薬物動態 29(2), 223-226, 2014
… Caco-2 is a widely used cell model in drug absorption and P-glycoprotein (P-gp, <i>MDR1</i>) substrate identification. … Long-term vinblastine treatment of Caco-2 cells could increase the expression of P-gp; … thus, the vinblastine resistant Caco-2 (Caco-2 vbl) cells can be used as a rapid and sensitive alternative model in identifying P-gp substrates. …
NAID 130004463373

Lack of Pharmacokinetic Interaction between Pilsicainide and Rifampicin in Healthy Volunteers

SHIGA Tsuyoshi,HASHIGUCHI Masayuki,NAKANURA Koichi,SHIMIZU Mikiko,SHIMIZU Kaoru,SUZUKI Atsushi,MOCHIZUKI Mayumi,HAGIWARA Nobuhisa
臨床薬理 = Japanese journal of clinical pharmacology 44(4), 301-305, 2013-07-31
… It has been hypothesized that a P-glycoprotein (P-gp)-induced transport mechanism may mediate the intestinal absorption and the renal excretion of pilsicainide. … We evaluated whether rifampicin, a known inducer of P-gp, affects the pharmacokinetics of pilsicainide after oral dosing in healthy subjects. …
NAID 10031190916